JP2005519908A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519908A5
JP2005519908A5 JP2003562099A JP2003562099A JP2005519908A5 JP 2005519908 A5 JP2005519908 A5 JP 2005519908A5 JP 2003562099 A JP2003562099 A JP 2003562099A JP 2003562099 A JP2003562099 A JP 2003562099A JP 2005519908 A5 JP2005519908 A5 JP 2005519908A5
Authority
JP
Japan
Prior art keywords
compound
methyl
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003562099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519908A (ja
JP4213595B2 (ja
Filing date
Publication date
Priority claimed from GBGB0201508.9A external-priority patent/GB0201508D0/en
Application filed filed Critical
Publication of JP2005519908A publication Critical patent/JP2005519908A/ja
Publication of JP2005519908A5 publication Critical patent/JP2005519908A5/ja
Application granted granted Critical
Publication of JP4213595B2 publication Critical patent/JP4213595B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003562099A 2002-01-23 2003-01-22 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド Expired - Fee Related JP4213595B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds
PCT/EP2003/000613 WO2003062220A1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008208640A Division JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Publications (3)

Publication Number Publication Date
JP2005519908A JP2005519908A (ja) 2005-07-07
JP2005519908A5 true JP2005519908A5 (enExample) 2005-12-22
JP4213595B2 JP4213595B2 (ja) 2009-01-21

Family

ID=9929594

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003562099A Expired - Fee Related JP4213595B2 (ja) 2002-01-23 2003-01-22 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド
JP2008208640A Expired - Fee Related JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008208640A Expired - Fee Related JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Country Status (15)

Country Link
US (5) US7557105B2 (enExample)
EP (3) EP1783126A3 (enExample)
JP (2) JP4213595B2 (enExample)
KR (2) KR100778163B1 (enExample)
CN (2) CN101468984A (enExample)
AT (1) ATE380807T1 (enExample)
BR (1) BR0307058A (enExample)
CA (1) CA2474104C (enExample)
DE (1) DE60318013T2 (enExample)
ES (2) ES2503734T3 (enExample)
GB (1) GB0201508D0 (enExample)
IL (2) IL162979A (enExample)
MX (1) MXPA04007130A (enExample)
PT (2) PT1470120E (enExample)
WO (1) WO2003062220A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419239T1 (de) * 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
JP4834553B2 (ja) * 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とc−kitキナーゼ阻害物質との併用
MEP3808A (xx) * 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
EP2009008A1 (en) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物,制备方法及其用途
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2008153974A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規ヘテロ環化合物およびその使用
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
KR101513326B1 (ko) * 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
JP2011515685A (ja) * 2008-03-26 2011-05-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 基質結合ビーズを長期間保存する方法
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
PT812195E (pt) * 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Similar Documents

Publication Publication Date Title
JP2005519908A5 (enExample)
CA2474104A1 (en) N-oxides of n-phenyl-2-pyrimidine-amine derivatives
JP5656874B2 (ja) Pde9阻害剤として使用されるアミノヘテロ環化合物
JP2008509187A5 (enExample)
EP0960106B1 (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2002520416A5 (enExample)
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
CA2416274A1 (en) N-phenyl-2-pyrimidine-amine derivatives
JP2005511699A5 (enExample)
JP2016507581A (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP2005508923A5 (enExample)
PT2420491E (pt) Compostos de piperidina 3,5-substituída como inibidores de renina
JP2006501201A5 (enExample)
JP2020529995A (ja) 行動の変化の治療方法
JP2005532397A5 (enExample)
JP2005508969A5 (enExample)
JP2003516994A5 (enExample)
JPH06500099A (ja) Cns疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
JP2003529597A5 (enExample)
US8716292B2 (en) Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
RU2007101522A (ru) Диарилметилпиперазиновые производные, их получение и применение